Introducing Dr. Rachel B Wagman: A Leading Clinical Advisor Joins Entera Bio’s Scientific Advisory Board
JERUSALEM, May 15, 2024 - Entera Bio Ltd. (NASDAQ: ENTX), a pioneering company in the development of orally delivered peptides and small therapeutic proteins, has recently announced the appointment of Dr. Rachel B Wagman, MD, FACE, FACP, as their Key Clinical Advisor and a distinguished member of its Scientific Advisory Board. With over two decades of experience in metabolic bone disease and women’s health research and drug development, Dr. Wagman’s addition to Entera Bio’s team promises to drive significant advancements in their mission to revolutionize oral drug delivery.
Dr. Wagman’s remarkable track record in the field of metabolic bone disease speaks for itself. Throughout her career, she has successfully propelled the development of five molecules, including teriparatide (Forteo), denosumab (Prolia), and romosozumab (Evenity), through the entire clinical development process, from initial stages to registration and lifecycle management. Her expertise and leadership have been instrumental in bringing cutting-edge treatments to market, providing hope and life-changing options to patients suffering from osteoporosis.
Entera Bio, renowned for its commitment to developing innovative oral delivery technologies, is thrilled to have Dr. Wagman on board. With her extensive research and development background, she is well-positioned to provide valuable insights and guidance to the company’s scientific team, enabling them to push the boundaries of drug delivery even further. Dr. Wagman’s appointment not only emphasizes Entera Bio’s dedication to advancing oral peptide and protein therapeutics but also underscores their commitment to putting patients first by offering convenient, effective, and accessible treatment options.
The inclusion of Dr. Wagman as a Key Clinical Advisor and Scientific Advisory Board member signifies Entera Bio’s strategic approach to leveraging world-class expertise in their pursuit of groundbreaking advancements. By integrating key opinion leaders like Dr. Wagman into their team, the company ensures that they remain at the forefront of scientific innovation, setting new industry standards in oral drug delivery. Her wealth of experience in metabolic bone diseases and women’s health research makes her a formidable asset to Entera Bio, positioning the company for continued success in this rapidly evolving field.
Entera Bio’s CEO, expressing his excitement at Dr. Wagman’s appointment, remarked, We are honored to welcome Dr. Wagman to our team. Her profound expertise and vast knowledge in metabolic bone disease will be invaluable as we progress our ongoing clinical programs. Dr. Wagman’s immense contributions in advancing osteoporosis treatments speak to her unwavering dedication to improving patient care.
As Entera Bio embarks on the next phase of their journey, Dr. Wagman’s appointment highlights the company’s commitment to accelerating the development of orally delivered peptides and small therapeutic proteins. With her guidance and expertise, Entera Bio aims to overcome the inherent challenges of oral drug delivery, offering innovative and patient-centric solutions that have the potential to transform the treatment landscape for a wide range of diseases and conditions.
In conclusion, Dr. Wagman’s appointment as Key Clinical Advisor and Scientific Advisory Board member at Entera Bio reflects the company’s dedication to attracting top talent and leveraging their expertise to drive innovation in oral drug delivery. With her extensive experience in metabolic bone diseases, Dr. Wagman’s inclusion strengthens the company’s ability to develop groundbreaking treatments and furthers its mission to improve patient lives worldwide.
Comments